Invizyne Technologies (IZTC) Competitors $15.08 +0.18 (+1.21%) As of 05/20/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IZTC vs. ARCT, TRDA, OLMA, ITOS, BNTC, FULC, DBVT, ACB, HRTX, and SEPNShould you be buying Invizyne Technologies stock or one of its competitors? The main competitors of Invizyne Technologies include Arcturus Therapeutics (ARCT), Entrada Therapeutics (TRDA), Olema Pharmaceuticals (OLMA), iTeos Therapeutics (ITOS), Benitec Biopharma (BNTC), Fulcrum Therapeutics (FULC), DBV Technologies (DBVT), Aurora Cannabis (ACB), Heron Therapeutics (HRTX), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry. Invizyne Technologies vs. Arcturus Therapeutics Entrada Therapeutics Olema Pharmaceuticals iTeos Therapeutics Benitec Biopharma Fulcrum Therapeutics DBV Technologies Aurora Cannabis Heron Therapeutics Septerna Arcturus Therapeutics (NASDAQ:ARCT) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk, community ranking and dividends. Does the MarketBeat Community favor ARCT or IZTC? Arcturus Therapeutics received 450 more outperform votes than Invizyne Technologies when rated by MarketBeat users. CompanyUnderperformOutperformArcturus TherapeuticsOutperform Votes45066.47% Underperform Votes22733.53% Invizyne TechnologiesN/AN/A Is ARCT or IZTC more profitable? Invizyne Technologies has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -36.39%. Invizyne Technologies' return on equity of 0.00% beat Arcturus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Arcturus Therapeutics-36.39% -22.39% -14.81% Invizyne Technologies N/A N/A N/A Do analysts rate ARCT or IZTC? Arcturus Therapeutics currently has a consensus target price of $57.80, indicating a potential upside of 375.72%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Arcturus Therapeutics is more favorable than Invizyne Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to ARCT or IZTC? In the previous week, Arcturus Therapeutics had 14 more articles in the media than Invizyne Technologies. MarketBeat recorded 14 mentions for Arcturus Therapeutics and 0 mentions for Invizyne Technologies. Arcturus Therapeutics' average media sentiment score of 0.60 beat Invizyne Technologies' score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Arcturus Therapeutics Positive Invizyne Technologies Neutral Do insiders & institutionals hold more shares of ARCT or IZTC? 94.5% of Arcturus Therapeutics shares are held by institutional investors. 16.6% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has better valuation and earnings, ARCT or IZTC? Invizyne Technologies has lower revenue, but higher earnings than Arcturus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcturus Therapeutics$131.27M2.51-$29.73M-$2.53-4.80Invizyne TechnologiesN/AN/AN/AN/AN/A SummaryArcturus Therapeutics beats Invizyne Technologies on 10 of the 13 factors compared between the two stocks. Get Invizyne Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for IZTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IZTC vs. The Competition Export to ExcelMetricInvizyne TechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$94.28M$2.93B$5.35B$8.38BDividend YieldN/A1.72%5.22%4.10%P/E RatioN/A30.5026.8419.71Price / SalesN/A400.15391.39116.98Price / CashN/A168.6838.2534.62Price / BookN/A3.286.794.50Net IncomeN/A-$72.17M$3.23B$248.18M7 Day Performance3.64%4.28%4.07%1.14%1 Month Performance39.11%7.62%12.52%15.20%1 Year PerformanceN/A-28.15%16.83%6.56% Invizyne Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IZTCInvizyne TechnologiesN/A$15.08+1.2%N/AN/A$94.28MN/A0.00N/AARCTArcturus Therapeutics2.9583 of 5 stars$11.95+3.1%$58.80+392.1%-58.4%$324.10M$138.39M-5.38180Gap UpTRDAEntrada Therapeutics2.9644 of 5 stars$8.50-3.6%$25.67+202.0%-46.2%$322.60M$172.22M5.35110News CoverageAnalyst ForecastAnalyst RevisionOLMAOlema Pharmaceuticals2.2991 of 5 stars$4.61-3.2%$27.67+500.1%-46.6%$315.14MN/A-2.1170Positive NewsGap UpITOSiTeos Therapeutics2.9935 of 5 stars$8.12+17.3%$25.50+214.0%-53.8%$310.79M$35M-2.5890Analyst RevisionGap UpHigh Trading VolumeBNTCBenitec Biopharma2.4167 of 5 stars$12.89-1.9%$24.71+91.7%+33.0%$302.28M$80,000.00-8.5420News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionFULCFulcrum Therapeutics0.7777 of 5 stars$5.59-1.6%$7.71+38.0%-15.5%$301.74M$80M-18.03100DBVTDBV Technologies3.0148 of 5 stars$10.66+5.2%$15.50+45.4%+52.4%$291.98M$15.73M-2.3780Positive NewsGap UpACBAurora Cannabis0.6152 of 5 stars$5.19+2.6%N/A-27.8%$291.75M$320.81M103.821,340News CoverageHRTXHeron Therapeutics3.8862 of 5 stars$1.90-7.3%$5.50+189.5%-43.5%$289.87M$148.52M-10.55300SEPNSepterna2.0614 of 5 stars$6.46-7.4%$33.00+410.8%N/A$287.57M$1.08M0.00N/AEarnings ReportAnalyst RevisionGap Down Related Companies and Tools Related Companies Arcturus Therapeutics Alternatives Entrada Therapeutics Alternatives Olema Pharmaceuticals Alternatives iTeos Therapeutics Alternatives Benitec Biopharma Alternatives Fulcrum Therapeutics Alternatives DBV Technologies Alternatives Aurora Cannabis Alternatives Heron Therapeutics Alternatives Septerna Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IZTC) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invizyne Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invizyne Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IZTC Stock Free IZTC Stock Alerts